Skip to main content

Blepharospasm

2
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
Botulinum Toxin Type A 900kDaPhase 41 trial
botulinum toxin type AN/A1 trial
Active Trials
NCT00535938Completed1,372Est. Sep 2013
NCT00761592Completed65Est. Jan 2008
Essential Pharmaceuticals
1 program
1
Cannabidiol Oral Solution [Epidiolex]Phase 2/31 trial
Active Trials
NCT04423341Completed12Est. Oct 2021
Ipsen
IpsenChina - Tianjin
2 programs
Post Marketing Surveillance Study of DysportN/A1 trial
Botulinum toxin type APHASE_21 trial
Active Trials
NCT00210431Completed783Est. Jun 2006
NCT00234507Completed120Est. May 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieBotulinum Toxin Type A 900kDa
Essential PharmaceuticalsCannabidiol Oral Solution [Epidiolex]
IpsenBotulinum toxin type A
AbbViebotulinum toxin type A
IpsenPost Marketing Surveillance Study of Dysport

Clinical Trials (5)

Total enrollment: 2,352 patients across 5 trials

NCT00761592AbbVieBotulinum Toxin Type A 900kDa

Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm

Start: Jul 2006Est. completion: Jan 200865 patients
Phase 4Completed
NCT04423341Essential PharmaceuticalsCannabidiol Oral Solution [Epidiolex]

Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm

Start: May 2020Est. completion: Oct 202112 patients
Phase 2/3Completed
NCT00234507IpsenBotulinum toxin type A

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

Start: Jan 2003Est. completion: May 2004120 patients
Phase 2Completed
NCT00535938AbbViebotulinum toxin type A

MDs on Botox Utility (MOBILITY)

Start: Sep 2007Est. completion: Sep 20131,372 patients
N/ACompleted
NCT00210431IpsenPost Marketing Surveillance Study of Dysport

Post Marketing Surveillance Study of Dysport

Start: Oct 2004Est. completion: Jun 2006783 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.